Skip to main
NUVB
NUVB logo

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio Inc's revenue from collaboration and license agreements saw a substantial increase to $5.4 million, primarily driven by higher service, supply, and royalty income. The strong month-to-month sales growth of taletrectinib, with a notable 25% increase, underscores the drug’s potential market momentum as it addresses critical therapeutic needs in naïve and struggling ROS1+ non-small cell lung cancer patients. Additionally, the favorable side effect profile of both taletrectinib and Ibtrozi, which has gained preferred status in clinical guidelines, positions Nuvation Bio advantageously within the oncology market, supporting a positive outlook for the company's financial prospects.

Bears say

Nuvation Bio Inc faces significant challenges that contribute to a negative financial outlook. The company's core assets, including its key product candidate taletrectinib, may encounter setbacks in clinical trials, which raises questions about their efficacy and safety, potentially leading to halted development and downward pressure on the stock. Additionally, competition from established market participants and metrics indicating trial enrollment delays or strategic missteps could further impair the company's growth prospects and overall valuation.

Nuvation Bio (NUVB) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Nuvation Bio (NUVB) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.